BenevolentAI has acquired a drug discovery and development facility on the Babraham Research Campus in Cambridge (UK) for an undisclosed amount.   The acquisition creates a unique AI-enabled research centre that can radically reduce the time it takes for drug candidates to enter clinical testing and deliver significantly higher success rates in treating or curing disease. The facility has a large scientific team with deep expertise in assay development and screening, medicinal and synthe...